about
Efficacy of Mesenchymal Stromal Cell Therapy for Acute Lung Injury in Preclinical Animal Models: A Systematic ReviewThe coagulopathy of acute sepsisChronic filarial infection provides protection against bacterial sepsis by functionally reprogramming macrophagesTreating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.Carbon monoxide in the treatment of sepsisIncreased Dicarbonyl Stress as a Novel Mechanism of Multi-Organ Failure in Critical IllnessSepsis: in search of cure.Inflammation in AKI: Current Understanding, Key Questions, and Knowledge Gaps.Engineering control into medicineTherapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes.Therapeutic interventions in sepsis: current and anticipated pharmacological agentsDysregulation of intracellular calcium transporters in animal models of sepsis-induced cardiomyopathyGenomic responses in mouse models greatly mimic human inflammatory diseases.Mesenchymal stem cells as a therapeutic tool to treat sepsis.Recognizing and managing sepsis: what needs to be done?On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death.Lipopolysaccharide Cross-Tolerance Delays Platelet-Activating Factor-Induced Sudden Death in Swiss Albino Mice: Involvement of Cyclooxygenase in Cross-ToleranceSirtuin-2 Regulates Sepsis Inflammation in ob/ob MiceParamedic Recognition of Sepsis in the Prehospital Setting: A Prospective Observational StudyGenomic landscape of the individual host response and outcomes in sepsis: a prospective cohort studyCould Biomarkers Direct Therapy for the Septic Patient?New paradigms in sepsis: from prevention to protection of failing microcirculation.Escherichia coli Braun Lipoprotein (BLP) exhibits endotoxemia - like pathology in Swiss albino mice.Validation of a free fall acrobatics intervention protocol to reduce neck loads during parachute opening shock.The role of indoleamine 2,3-dioxygenase-aryl hydrocarbon receptor pathway in the TLR4-induced tolerogenic phenotype in human DCs.Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis.Pro-Resolving Molecules-New Approaches to Treat Sepsis?A path to precision in the ICU.Mitochondrial Dysfunction and Immune Cell Metabolism in Sepsis.Immune-modulating therapy in acute pancreatitis: fact or fiction.Sepsis, oxidative stress, and hypoxia: Are there clues to better treatment?IMMUNE CELL PHENOTYPE AND FUNCTION IN SEPSIS.Cell-Derived Nanoparticles are Endogenous Modulators of Sepsis With Therapeutic Potential.Recent developments in severe sepsis research: from bench to bedside and back.Host-Pathogen Interface: Progress in Understanding the Pathogenesis of Infection Due to Multidrug-Resistant Bacteria in the Intensive Care Unit.Role of microRNAs in sepsis.Early innate immune responses to bacterial LPS.Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome.Pathogenic, immunologic, and clinical aspects of sepsis - update 2016.Metabolism, Metabolomics, and Nutritional Support of Patients with Sepsis.
P2860
Q26773048-3D060156-450E-4077-A20F-10DA37546E82Q26826950-13DAC489-E5DD-4132-A95E-6544FD0D3D9BQ27321497-2D290808-7D85-4BA1-B266-795C63F946F5Q28076034-BA34EB03-EB3C-418E-89D6-2C27205BF7C3Q28085488-618BFF08-4CEF-4416-B0D9-9EA785F33F6BQ30236047-CD3730B0-88AD-4967-BB43-B2BE2BFE6784Q30251753-E4BEB52B-2D93-42D2-B9E8-B207375AE432Q30278352-6478FAED-C18F-42E7-A9AF-7C4450CE2A3DQ30300786-4CD8354F-37FC-4B14-A165-1765F0A042BCQ33918856-4FD4A66F-4A70-455D-9D7B-5C66AB70D855Q34427050-F6C5B773-D136-4646-AB63-ECE688BA9697Q34725636-DEB432F7-3B6E-470D-A1E2-96EB4B35BC89Q35037958-558C57BC-5FD9-4695-90BC-F99923C150C4Q35205670-9231ECE5-222F-4732-8FD4-3394276CC302Q35541383-FEB49F25-68B9-4A53-B099-20C4E5888719Q35765830-2600871D-EE21-4E4E-8ADB-541EB1D45E2AQ35985649-13B418F3-D93A-486B-A204-730D96951AB7Q36097432-F7620E45-E80C-41DA-858F-0C2CDF76D54BQ36718863-38558FA8-0A9D-43AB-AE82-7F4278692994Q36764754-AE741A7D-A0B5-438E-9F71-4022D9A9A618Q36852546-D216B94F-4FD3-4533-97E4-DC16397873FDQ37238202-7886D0D1-FF23-46F7-81F1-69508E43C820Q37307082-EEB9417A-935E-4401-B8B8-B3E95CFA26F1Q37425555-AF150CBB-125B-4C51-9872-E4712D077F48Q37678976-AC44BB35-6427-43E4-855A-C1B70A752EEDQ37688733-954CE7F1-7838-40B2-97FC-75A0DF018ACFQ37728979-8242EA65-55D7-4CEC-8C8E-8289D4DC4661Q37733894-BC4EEE2D-F6A7-4642-8B33-284024FCCE0FQ37739000-0EE2E9BB-2678-431A-BE9D-E8F2276AAA41Q38266870-C2330680-0D93-423D-AC76-848DE1C87CDBQ38389032-FDF4EF95-BECB-4FA8-B07C-D70E7465037AQ38412875-8573D349-B608-4FB9-BEE1-22FC2186AE97Q38715255-F3F89292-4C66-4663-8818-BA690F15C1CBQ38724278-200E07CA-F7BC-46C7-BF00-0A6601C24954Q38735259-A4820B9F-A640-4E01-8C59-F9905254189CQ38750932-0326F706-D4CF-48C1-93BC-5AE507DA3E0EQ38795578-AC1D0D5F-E0B8-4407-AA75-F0DDFF1B8052Q38820842-1DC3C6AC-1BCB-4121-8538-375B33BC0C49Q38830793-8D958957-909F-4422-9062-DB45AFF2A245Q38845332-926347A9-B2F9-4187-B1CD-54E4611A10A1
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Why have clinical trials in sepsis failed?
@en
Why have clinical trials in sepsis failed?
@nl
Защо клиничните изпитвания при сепсис не са успели?
@bg
type
label
Why have clinical trials in sepsis failed?
@en
Why have clinical trials in sepsis failed?
@nl
Защо клиничните изпитвания при сепсис не са успели?
@bg
prefLabel
Why have clinical trials in sepsis failed?
@en
Why have clinical trials in sepsis failed?
@nl
Защо клиничните изпитвания при сепсис не са успели?
@bg
P1476
Why have clinical trials in sepsis failed?
@en
P2093
John C Marshall
P304
P356
10.1016/J.MOLMED.2014.01.007
P577
2014-02-24T00:00:00Z